IC2PerMed | BBMRI-ERIC: Making New Treatments Possible
FontsA A
ContrastA A
Newsletter sign-up
I give permission for BBMRI-ERIC to send me their newsletter and emails about subjects which they think may be of interest to me. I can unsubscribe from all emails at any time. I understand that my information will be processed according to BBMRI-ERIC's privacy notice.

IC2PerMed

IC2PerMed: Integrating China in the International Consortium for Personalised Medicine

Topic: SC1-HCO-01-2018-2019-2020  Actions in support of the International Consortium for Personalised Medicine

Type of Action: CSA

Duration: 48 months

Start date: 1 Jan 2020

Grant agreement: 874694

Web: not yet available

Total request Grant by Consortium: €1,691,437.50

Total request Grant by BBMRI-ERIC: €219,687.50

Linked Third Parties/BBMRI-ERIC Framework Agreement: none

Benefit/tasks for BBMRI-ERIC: BBMRI-ERIC is involved in WP1 (Mapping of PM policies and programmes in Europe and China), WP2 (Knowledge synthesis on the identification, transferability and scaling up of international standards in personalized medicine), WP3 (Foster research collaboration between EU and China) including leading Task 3.3 (Setting a concrete collaboration scenario on Biobanks), WP4 (Communication, dissemination, outreach and exploitation) and WP5 (Project Management)

Abstract

Personalised Medicine (PM) approaches, thanks to the latest technological advances notably in the fields of biomedical and digital technologies, prove their potential to improve healthcare and underpin more efficient and sustainable health systems. PM is at the top of the European Commission research agenda, with funding devoted to projects along the entire value chain.

In China, PM is attracting massive interest, with the government capitalising on its expertise in biotechnology, computing hardware and the ability to put in place the infrastructures for supporting large bioinformatics projects. Turning PM into an opportunity for all citizens and patients requires the engagement of all stakeholders, in order to define common research and development approaches, standards, and priorities, and to scale up the collaboration at the International level.

In order to respond to these challenges, the EU supports actions developed within the International Consortium for Personalised Medicine (ICPerMed). IC2PerMed project will provide key solutions for enabling the convergence under ICPerMed consortium of European and Chinese stakeholders towards a common approach of PM research, innovation, development and implementation involving policy makers and healthcare beneficiaries, by:

  • mapping policies, programmes, standards and initiatives related to PM in Europe in China for identifying the opportunities for research collaborations;
  • structuring its developments upon an ecosystem of European and Chinese experts, collaborating in Working Groups centred on ICPerMed Action plan priorities;
  • setting bridges with key organisms involved in the definition and implementation of PM and healthcare systems in both economic areas, both on benefits for coordinated approaches for research and on concrete developments taking place within and along the project;
  • inserting its developments in international contexts, through ICPerMed and its involvement in relevant initiatives and networks.

 

IC2PerMed is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874694.

European emblem EU


The website was co-funded within ADOPT BBMRI-ERIC, a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 676550.
We use cookies to analyse the traffic on our websites. All personal data is anonymized and not shared with third parties! Click here for more information.
Accept